by Viola Volatility | Oct 21, 2016 | Business, Viola V.
Another expiration Friday, and we closed $SPX down. Is this the sign of the start of a down move that has been long in coming? Who the heck knows- well…except the rulers in the Eccles Building, and whomever they deign to tell. SO what to do for the rest of the day? Well, these are the levels in the /ES I am looking at.
$ES_F today:
- Looking down: if 2128.50 is broken, should be down
gap at 2123.25 good reversal point if drop at open
2118 important support for bull case
- Looking up: if 2128.50 remains, good upside potential
gap at 2137
shelf at 2138.50
shelf at 2141.25
- Up target is 2155 where the island formed between 10/7-10/11 resides
- Another trade I am working is selling a couple of puts in the $ES_F for expiry in week three- 28 days until expiration, around the 2020 option. I will take it off at 50% profit, it that happens.
What else is going on? We are fighting the down move in the $ES_F futures right now, but that is nothing new. We have been having a frustrating, schizoid market the last couple of days with big drops, lots of sideways chop, and big pops. I lost money- I admit it. I got whirled up in the blender. But I am woman enough to put on my big girl pants, and dive back in today. I think.
What I would like to see is the ES retest the low around 2107.50. I have been holding shorts for a while now, as a core position, waiting for that number to hit. Of course, there are a lot of things I want, not the least is for this to happen, and yes, I remain disappointed, all the while still wearing my big girl pants.
It’s been a tough week and I can sense the exhaustion amongst a lot of traders. Unfortunately there’s really nothing to do but remain patient and vigilant. We have had basically a year long sideways market with a quick downside correction mid year. You know this can change in an instant. So, I want to stay nimble and emotionally balanced so that when an entry opportunity presents itself, I am alert and emotionally ready to pounce.
Happy trading- and drink a lot this weekend. I will.
-Viola V.
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
by Alpha | Oct 21, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
4. CHK:$CHK upgraded to Neutral at Nomura, upgraded to Neutral at BankofAmerica
6. PM, RAI:Sept 15 Goldman downgraded $RAI & Upgrade $PM, Citi intiated $RAI at Buy w/ $57 PT. Now BAT is buying remaining RAI stake.
DOWNGRADES
2. PM, RAI:Sept 15 Goldman downgraded $RAI & Upgrade $PM, Citi intiated $RAI at Buy w/ $57 PT. Now BAT is buying remaining RAI stake.
EARNINGS
Trending Social Alerts
1. GE:$GE General Electric Q3 16 Earnings Results: -EPS: $0.32 -Revenue: $29.3B
2. MSFT:A 13-year ascent, then leveled off for 17 years. Here’s the full view of $MSFT since its 1986 IPO. Who’s got a cost…
3. MRK:$MRK’s KEYNOTE-045 Studying KEYTRUDA® in Advanced Bladder Cancer Meets Primary Endpoint and Stops Early
6. TWLO:Twilio prices secondary offering at $40. Remember it was a $70 “hot-IPO” three weeks ago? $TWLO
Trending News Headlines
1. Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. “The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,” said Dr. Roger M. Perlmutter , president, Merck Research Laboratories . “We look forward to sharing the findings from this study with the medical community and with regulatory
2. No partner in sight, Twitter faces tough solo choices
The apparent lack of interest in Twitter Inc by potential suitors may force the social media company to consider a route anathema to aspiring tech startups: a major restructuring and cutting some its nearly 4,000 employees.
Technology News
Today’s Economic Calendar
10:15 Daniel Tarullo speech
1:00 PM Baker-Hughes Rig Coun
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
See you in the chat room
by Alpha | Oct 20, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
DOWNGRADES
EARNINGS
Trending Social Alerts
1. VZ:Verizon Reports Q3 EPS $1.01 vs. Est. $0.99, Rev. $30.9B vs. Est. $31.09B $VZ
3. WBA:Walgreens Boots Alliance Reports Q4 Adj. EPS $1.07 vs $0.99 Est., Sales $28.6B vs $29.1B Est. $WBA
6. ONVO:$ONVO prices 9m shares at 2.75/share
Trending News Headlines
1. Puma Bio’s desperate money grab signals breast cancer drug trouble
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma’s stock price. Get the deal done, even if you have to sell it to the shorts.
2. Snoopy Has Been Fired by MetLife
MetLife decided earlier this year to part with most of its U.S. life-insurance business. Now it is cutting ties with Snoopy.
3. European Central Bank Leaves Rates on Hold
The European Central Bank kept all of its key interest rates unchanged, matching expectations that its policy would remain in a holding pattern as inflation gradually picks up in the currency bloc.
4. Draghi Keeping Up Suspense on Future of ECB Stimulus Plan
Instead of expanding stimulus just now, Mario Draghi might settle for keeping up the suspense surrounding it.
5. Puma Biotechnology Prices Public Offering of Common Stock | Business Wire
Puma Biotechnology announced the pricing on its proposed common stock offering.
Technology News
Today’s Economic Calendar
8:30 Initial Jobless Claims
8:30 Philly Fed Business Outlook
9:45 Bloomberg Consumer Comfort Index
10:00 Leading Indicators
10:00 Existing Home Sales
10:30 EIA Natural Gas Inventory
4:30 PM Money Supply
4:30 PM Fed Balance Sheet
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
See you in the chat room
by Viola Volatility | Oct 19, 2016 | Business, Viola V.
What does a trader do in a captured market?
The last couple of days have been mind numbing for me. Watching the ticks bounce around in a five to seven point range for hours makes me want to scream, throw things, and internet shop for needless items. Seems the solution to this sort of boredom is, natch, obsessing about the election! Yes folks, tonight is the third and final debate for this presidential election. And, I can wait- indefinitely.
This train is moving down the track, and it is relentless. Clinton, Trump, Clinton, Trump- I hear the sound of the wheels chanting that annoying rhythm as it clatters past. The candidates’ claims have become so outrageous I don’t care what either of them has to say tonight. In my book, they are both awful choices for the ruler of the free world. So what does this have to do with trading? I was musing about the effect of a Clinton victory yesterday, and came to the conclusion that since everyone has already decided she is the winner, the market probably has this outcome baked in. So, how much more can the market pop with a Clinton win? I think that Trump is the dark horse- the market might see a Brexit-type reaction if he squeaks in with the win.
How to trade this?
Beats me- but I do know, any type of volatility would be welcome, since I like to sell puts and calls when volatility is high. I might be inclined to do a short straddle in the SPY the day of the election- depends on if the vol is high. $EWW has been waxing and waning with this election- Trump’s Mexico comments seem to move that market. Also, the coal stocks and the pharma stocks seem to be hanging on Clinton’s word; there may be a trade in $IBB or $CNX. What is clear is that in the last decade, coal has gone from being the source of half of the country’s electricity to just one-third, while natural gas has risen from 21% to 31% and renewables have gained as well. The coal industry has been battered and beaten during the Obama administration. In fact, Consol Energy is one of the few coal companies to survive the fracking revolution of the last decade. A Trump election would likely be perceived as a big win for the industry, considering his support in coal country and his promises to reopen mines.
Trade safe out there today, and have fun. See you in the chat room
– Viola V.
There’s a preventable crisis facing America, and yet neither of the major-party candidates has said much, if anything, about it. To that point, the words “retirement” and “Social Security” have not been uttered in the first two presidential debates. Let’s see what happens in the final debate on Wednesday night.
If you enjoy the content at SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
by Alpha | Oct 19, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
1. COST:$COST upgraded to Buy at Northcoast Research.
6. SQ:is it Dorsey’s birthday? $SQ initiated at csfb and upgraded at loop
7. TWTR:$TWTR upgraded to Hold at Loop Capital – PT $16
DOWNGRADES
4. WFC:$WFC downgraded to Market Perform at FBR Capital
EARNINGS
Trending Social Alerts
1. MS:Morgan Stanley Q3 EPS $0.81 vs $0.63 est, Revenue $8.91B vs $8.16B est. $MS
2. INTC:Can Intel transition itself into a true 21st century tech leader? $INTC down 5% #premarket after guidance fails to impress.
3. STJ:MW is releasing new $STJ videos today. Stay tuned… $ABT
4. CERU:$CERU $20 Million Firm Commitment At-The-Market Stock Purchase Agreement with Aspire Capital. 800K shares at $1.25/share
6. HAL:Halliburton Q3 EPS $0.01 vs $ est, Revenue $3.8B vs $3.9B est. $HAL
8. USB:US Bancorp Q3 EPS $0.84 vs $0.84 est, Revenue $5.38B vs $5.35B est $USB
Trending News Headlines
1. Celgene skips the placebo, fails drug development 101
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
2. Abbott’s third-quarter revenue rises nearly 3 percent
Abbott Laboratories (ABT.N), which is in the process of acquiring St. Jude Medical Inc (STJ.N), reported a nearly 3 percent rise in quarterly sales, fueled by strength in its generic drug and medical device businesses.
3. Salesforce’s M&A Target List Excluded Twitter
Months before Salesforce considered buying Twitter, the company was looking at more than a dozen acquisition targets that didn’t include the social-media giant, according to a leaked internal presentation for its board members.
4. John LaMattina on Twitter
“Despite Promising Early Data, The New Cholesterol Lowering Drug – PCSK9si – Has Significant Hurdles
5. Morgan Stanley Beats Estimates on Surge in Bond-Trading Revenue
Morgan Stanley reported a 57 percent increase in third-quarter profit as fixed-income trading revenue almost tripled, the biggest surge for that business on Wall Street.
6. Morgan Stanley Reports Third Quarter 2016: | Business Wire
Morgan Stanley (NYSE: MS) today reported net revenues of $8.9 billion for the third quarter ended September 30, 2016 compared with $7.8 billion a year
7. U.S. Bancorp Reports Third Quarter 2016 Earnings | Business Wire
U.S. Bancorp (NYSE: USB) today reported net income of $1,502 million for the third quarter of 2016, or $0.84 per diluted common share, compared with $
8. EU believes free trade deal with U.S. won’t be completed this year: source
The European Commission believes it is unlikely that negotiations with the United States over a free trade deal will be completed under the current U.S. administration, a Commission source told Reuters on the condition of anonymity on Wednesday.
9. Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day (NASDAQ:KITE)
Four New Clinical Programs Unveiled to Drive Long-Term Growth T cells 2.0 Next Generation Programming to Realize Full Potential of Cell Therapy …
10. BRIEF-St. Jude Medical Q3 earnings per share $0.73
St. Jude Medical Inc –
11. Tableau Software (DATA) Won’t Comment on Sale Rumors After Leak
In response to questions if the company is for sale after showing up on salesforce.com’s (NYSE: CRM) hacked…
12. Credit Suisse agrees to $110 million deal to settle Italy tax case: source
Credit Suisse CNGN.S has agreed in principle to pay about 100 million euros ($110 million) to settle its tax position in Italy in a case involving allegations it helped clients transfer undeclared funds offshore, a source with direct knowledge of the matter said on Tuesday.
13. Starbucks names China CEO, sees 5,000 stores there by 2021
Starbucks Corp (SBUX.O) on Wednesday named its first chief executive officer for China and said it plans to more than double its store count in that country to 5,000 by 2021.
14. How One Goldman Sachs Trader Made More Than $100 Million
One junk-bond trader at Goldman Sachs earned more than $100 million in trading profits earlier this year, an unusual gain at a time when new regulations have forced Wall Street to take fewer risks.
15. Morgan Stanley earnings: 81 cents per share, vs expected EPS of 63 cents
Morgan Stanley joined its Wall Street peers in the third quarter by easily topping profit expectations.
Technology News
Today’s Economic Calendar
7:00 MBA Mortgage Applications
8:30 Housing Starts
10:00 Atlanta Fed’s Business Inflation Expectations
10:30 EIA Petroleum Inventories
2:00 PM Fed’s Beige Book
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
See you in the chat room
by Alpha | Oct 18, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
DOWNGRADES
1. CMG:$CMG downgraded to Underperform at Raymond James, maintains Outperform rating at RBC Capital – PT CuT $465 from $485
7. YHOO:$YHOO downgraded to Hold at Needham
EARNINGS
Trending Social Alerts
1. NFLX:Chuckle of the morning: Wedbush, always bearish on $NFLX, raising its target from $50 to $60. @CNBC
2. DPZ:Domino’s Pizza Reports Q3 EPS $0.96 vs $0.89 Est., Sales $566.7M vs $542M Est. $DPZ
3. BLK:$BLK BlackRock Q3 16 Earnings Results: -Adj EPS: $5.14 -Revenue: $2.84B
4. JNJ:#JOHNSONandJOHNSON Q3 sales beats Wall St. forecast by 0.6% at $17.82bn, EPS 1.8% above fcast at $1.68 $JNJ
6. GS:#BREAKING: Goldman Sachs $GS Q3 Earnings Per Share , $4.88 vs. $3.79 expected
8. PM:$PM Philip Morris Q3 16 Earnings Results: -Adj EPS: $1.25 -Revenue: $6.98B
10. GLPG:$CELG GED-0301 only 15% responder rate for >50% cutoff, i.e. probably worse than placebo in $GLPG filgotinib trial…
12. STJ:$STJ St. Jude Medical, FDA And Top Pediatric Cardiology Experts Announce New Clinical Trial To Treat Congenital Heart Defects -Dow Jones
Trending News Headlines
1. UnitedHealth Boosts Forecast as It Puts Obamacare Woes in Past
UnitedHealth Group Inc. boosted its full-year profit forecast, as its health insurance and consulting businesses both recorded strong results following the company’s retreat from Obamacare, announced earlier this year.
2. The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si
The Medicines Company today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor.
3. Goldman Sachs Profit Climbs as Trading Revenue Surges
Goldman Sachs said its quarterly earnings rose 47% as the firm continues to rebound from a slow start to the year. Results beat expectations, pushing shares up premarket.
4. George Pearkes on Twitter
“Good lord. $DPZ”
5. Philip Morris Profit Tops Estimates, Helped by Higher Prices
Philip Morris International, the world’s largest publicly traded tobacco company, posted third-quarter profit that beat analysts’ estimates as higher cigarette prices boosted revenue.
6. Goldman Sachs earnings: $4.88 a share vs. expected EPS of $3.82
Analysts had expected Goldman Sachs to report third-quarter earnings per share of $3.82 on revenue of $7.42 billion, according to a consensus estimate from Thomson Reuters.
7. Goldman Sachs Profit Climbs as Trading Revenue Surges
Goldman Sachs said its quarterly earnings rose as the firm continues to rebound from a slow start to the year.
8. The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si
The Medicines Company today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor.
9. China Corporate Debt Window ‘Closing Quickly,’ IMF Paper Says
China urgently needs a plan to address a build up of corporate debt that is manageable but with a window to address it “closing quickly,” said an International Monetary Fund working paper.
10. Disney Dropped Twitter Pursuit Partly Over Image
Walt Disney Co. decided not to pursue a bid for Twitter Inc. partly out of concern that bullying and other uncivil forms of communication on the social media site might soil the company’s wholesome family image, according to people familiar with management’s thinking.
Technology News
Today’s Economic Calendar
8:30 Consumer Price Index
8:55 Redbook Chain Store Sales
10:00 NAHB Housing Market Index
4:00 PM Treasury International Capital
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
See you in the chat room